Advertisement
Screener

CYTOSORBENTS CORPORATION (CTSO) Debt / Equity

CYTOSORBENTS CORPORATION (CTSO) Debt / Equity

  • 2026-06-30: Debt/Equity Ratio -22.96.
  • 2026-03-31: Debt/Equity Ratio 7.73.
  • 2024-03-31: Debt/Equity Ratio 0.23.
  • 2023-12-31: Debt/Equity Ratio 0.21.

Complete source-backed debt/equity ratio history.

Available history
2015-12-31 to 2026-06-30
Data captured

Historical Debt/Equity Ratio

DateDebt/Equity Ratio
2026-06-30-22.96
2026-03-317.73
2024-03-310.23
2023-12-310.21
2023-09-300.27
2020-12-310
2020-09-300.19
2020-06-300.62
2020-03-310.71
2019-12-314.4
2019-09-302.23
2019-06-300.87
2019-03-310.66
2018-12-310.59
2018-09-300.49
2018-06-300.46
2018-03-310.68
2017-12-310.97
2017-09-301.05
2017-06-301.26
2017-03-31-3.14
2016-12-313.67
2016-09-303.55
2015-12-310

Annual Debt/Equity Ratio

DateDebt/Equity Ratio
2023-12-310.21
2020-12-310
2019-12-314.4
2018-12-310.59
2017-12-310.97
2016-12-313.67
2015-12-310

Similar stocks

Stock NameCountryMarket CapPE Ratio
ORASURE TECHNOLOGIES INC (OSUR)United States$0.272B-6.26
Anika Therapeutics, Inc. (ANIK)United States$0.272B-51.71
TriSalus Life Sciences, Inc. (TLSI)United States$0.283B-9.92
Mobia Medical, Inc. (MOBI)United States$0.293B
InfuSystem Holdings, Inc (INFU)United States$0.253B22.52
TREACE MEDICAL CONCEPTS, INC. (TMCI)United States$0.297B-4.32
UTAH MEDICAL PRODUCTS INC (UTMD)United States$0.238B20.93
PRO DEX INC (PDEX)United States$0.234B13.64
Embecta Corp. (EMBC)United States$0.319B2.10
Neuronetics, Inc. (STIM)United States$0.216B-3.25